Clinical trials: Lung Disorder
Non-small Cell Lung Cancer
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less time between treatments than in standard chemotherapy.
- Trial name
- NCT02157116
- Testing
- cisplatin, Docetaxel, Pegfilgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Duke University
SARS-CoV-2
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
- Trial name
- NCT04673149
- Testing
- GLS-5310
- Where
- South Korea
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Cystic Fibrosis
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
This study evaluated the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR)…
- Trial name
- NCT05274269
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 90 sites in Austria, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Asthma
Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®
The primary objective of the study is to establish whether budesonide/formoterol fumarate dihydrate (BF) Spiromax 160/4.5 micrograms (mcg) is as effective as Symbicort Turbohaler 200/6 mcg administered twice daily in participants…
- Trial name
- NCT01803555
- Testing
- Budesonide/Formoterol SPIROMAX®, SYMBICORT® TURBOHALER®
- Where
- 114 sites in Austria, Belgium and 14 more
- Volunteers
- 605 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Small Cell Lung Carcinoma
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung…
- Trial name
- NCT00143455
- Testing
- Etoposide + cisplatin, Irinotecan + cisplatin
- Where
- 67 sites in Austria, Belgium and 11 more
- Volunteers
- 485 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of Asian subjects with unresectable stage III non-small cell lung…
- Trial name
- INSPIRE (NCT01015443)
- Testing
- Tecemotide, Single low dose cyclophosphamide, Saline
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 285 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing
The purpose of this study is to determine whether OM-85 BV (Broncho-Vaxom)has any effect on respiratory infections, infection related wheezing attacks, beta-2 agonist use, duration of attacks and effect on serum cytokine levels.
- Trial name
- NCT00733226
- Testing
- OM-85 BV (Broncho-Vaxom)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Kecioren Education and Training Hospital
Skin Rash, Lung Cancer
Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)
1. Advanced NSCLC has a poor prognosis and the positive impact of chemotherapy is limited by the development of intrinsic and acquired resistance. 2.
- Trial name
- NCT01880515
- Testing
- Tetracycline
- Where
- Mexico
- Volunteers
- 107 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Bronchial Asthma
Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in…
- Trial name
- NCT00448435
- Testing
- GW815SF HFA MDI, salmeterol and fluticasone propionate
- Where
- 8 sites in Japan
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual…
- Trial name
- NCT03467425
- Testing
- FF/UMEC/VI, Inhaled Corticosteroid, LAMA
- Where
- 143 sites in Germany, Netherlands and 3 more
- Volunteers
- 3,109 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well…
- Trial name
- NCT01766817
- Testing
- BMS-986020
- Where
- 72 sites in United States, Australia and 4 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
COPD
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD…
- Trial name
- NCT04138758
- Testing
- Tiotropium bromide + Olodaterol, LABA/ICS
- Where
- United States
- Volunteers
- 42,953 people
- Sponsor
- Boehringer Ingelheim
COVID19
Study of Plasma Exchange in Severe COVID-19
The rationale in severe COVID19 infection is to undertake PEX to aid reduction of the hyperinflammation and reduce the morbidity and mortality to the lungs, but also systemically, such as the heart, kidneys and brain.
- Trial name
- COVIPLEX (NCT04623255)
- Testing
- OCTAPLAS
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University College, London
Bronchiolitis
A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis
The purpose of this study is to determine if nebulized hypertonic saline (or extra salty water mist) helps infants less than 12 months old hospitalized with bronchiolitis (or bad chest colds) get better enough to be discharged…
- Trial name
- NCT01488448
- Testing
- 3% sodium chloride, 0.9% sodium chloride
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Non-Small Cell Lung Carcinoma
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
This is a study to assess the efficacy and safety of pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV…
- Trial name
- NCT02142738
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 305 people
- Sponsor
- Merck Sharp & Dohme LLC
Intubated Infants Were Intend to Extubation Using Noninvasive Ventilation Strategies
A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants Following Extubation
Respiratory distress syndrome (RDS) is the main cause of respiratory failure in preterm neonates, its incidence varying from 80% to 25% depending on gestational age.When optimal prenatal care is provided, the best approach to…
- Trial name
- NCT03181958
- Testing
- NHFOV, NCPAP, NIPPV
- Where
- China
- Volunteers
- 1,493 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Asthma
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
- Trial name
- SITAR (NCT01591044)
- Testing
- R940343 1mg, R940343 2mg
- Where
- 59 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Rigel Pharmaceuticals
Covid19
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease.
- Trial name
- COPS-2003 (NCT04524663)
- Testing
- Camostat Mesilate, Standard of Care Treatment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Stanford University
Pneumonia, Malaria
Zambia Integrated Management of Malaria and Pneumonia Study
The purpose of the study is to demonstrate the effectiveness and feasibility of community-based management of pneumonia and malaria by community health workers (CHWs) in a rural district of Zambia.
- Trial name
- ZIMMAPS (NCT00513500)
- Testing
- Coartem and amoxicillin, Coartem
- Where
- Zambia
- Volunteers
- 3,125 people
- Sponsor
- Boston University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.